Document:

SECURITIES PURCHASE AGREEMENT

EXHIBIT 10.2

SECURITIES PURCHASE AGREEMENT

This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 20, 2017, by and between Force Protection Video Equipment Corp., a Florida corporation, with its address at 130 Iowa Lane, Suite 102, Cary, NC 27511 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, Great Neck, NY 11021 (the “Buyer”).

WHEREAS:

A. The Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “1933 Act”); and

B. Buyer desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a convertible note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal amount of $70,000.00 (together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with respect thereto in accordance with the terms thereof, the “Note”), convertible into shares of common stock, $0.0001 par value per share, of the Company (the “Common Stock”), upon the terms and subject to the limitations and conditions set forth in such Note.

NOW THEREFORE, the Company and the Buyer severally (and not jointly) hereby agree as follows:

1. Purchase and Sale of Note.

a. Purchase of Note.  On the Closing Date (as defined below), the Company shall issue and sell to the Buyer and the Buyer agrees to purchase from the Company such principal amount of Note as is set forth immediately below the Buyer’s name on the signature pages hereto.

b. Form of Payment.  On the Closing Date (as defined below),  the Buyer shall pay the purchase price for the Note to be issued and sold to it at the Closing (as defined below) (the “Purchase Price”) by wire transfer of immediately available funds to the Company, in accordance with the Company’s written wiring instructions, against delivery of the Note in the principal amount equal to the Purchase Price as is set forth immediately below the Buyer’s name on the signature pages hereto, and  the Company shall deliver such duly executed Note on behalf of the Company, to the Buyer, against delivery of such Purchase Price. 

c. 

1

Closing Date.  Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below, the date and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be 12:00 noon, Eastern Standard Time on or about October 23, 2017, or such other mutually agreed upon time.  The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the parties.

2. Buyer’s Representations and Warranties.  The Buyer represents and warrants to the Company that:

a. Investment Purpose.  As of the date hereof, the Buyer is purchasing the Note and the shares of Common Stock issuable upon conversion of or otherwise pursuant to the Note (such shares of Common Stock being collectively referred to herein as the “Conversion Shares” and, collectively with the Note, the “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the 1933 Act.

b. Accredited Investor Status.  The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited Investor”).

c. Reliance on Exemptions.  The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

d. Information.  The Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer.

 

e. Legends.  The Buyer understands that the Note and, until such time as the Conversion Shares have been registered under the 1933 Act; or may be sold pursuant to an applicable exemption from registration, the Conversion Shares may bear a restrictive legend in substantially the following form:

"THE SECURITIES REPRESENTED BY THIS INSTRUMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR (2) THE ISSUER OF SUCH 

2

SECURITIES RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE REASONABLY ACCEPTABLE TO THE ISSUER’S TRANSFER AGENT, THAT SUCH SECURITIES MAY BE PLEDGED, SOLD, ASSIGNED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS."

The legend set forth above shall be removed and the Company shall issue a certificate without such legend to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a) such Security is registered for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to an exemption from registration without any restriction as to the number of securities as of a particular date that can then be immediately sold, or (b) such holder provides the Company with an opinion of counsel, in form, substance and scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which opinion shall be accepted by the Company so that the sale or transfer is effected.  The Buyer agrees to sell all Securities, including those represented by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant to an exemption from registration, such as Rule 144, at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note.

f. Authorization; Enforcement. This Agreement has been duly and validly authorized.  This Agreement has been duly executed and delivered on behalf of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms.

3. Representations and Warranties of the Company.  The Company represents and warrants to the Buyer that:

a. Organization and Qualification.  The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated and conducted.  “Subsidiaries” means any corporation or other organization, whether incorporated or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership interest.

b. Authorization; Enforcement.  (i) The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the 

3

terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance and reservation for issuance of the Conversion Shares issuable upon conversion or exercise thereof) have been duly authorized by the Company’s Board of Directors and no further consent or authorization of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered by the Company by its authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and (iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

c. Capitalization.  As of the date hereof, the authorized common stock of the Company consists of 750,000,000 authorized shares of Common Stock, $0.0001 par value per share, of which 10,430,296 shares are issued and outstanding; and 93,043,863 shares are reserved for issuance upon conversion of the Note.  All of such outstanding shares of capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and non-assessable.  .

d. Issuance of Shares.  The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note in accordance with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

e. No Conflicts.  The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company or any of its Subsidiaries is a party, or (iii)  result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would not, individually or in the aggregate, have a Material Adverse Effect).  The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity.  “Material Adverse Effect” means any material adverse effect on the business, operations, assets, financial condition or prospects of the Company or its 

4

Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the agreements or instruments to be entered into in connection herewith.   

f. SEC Documents; Financial Statements.  The Company has filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “1934 Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein as the “SEC Documents”).  Upon written request the Company will deliver to the Buyer true and complete copies of the SEC Documents, except for such exhibits and incorporated documents.  As of their respective dates or if amended, as of the dates of the amendments, the SEC Documents complied in all material respects with the requirements of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.  None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof).  As of their respective dates or if amended, as of the dates of the amendments, the financial statements of the Company included in the SEC Documents complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto.  Such financial statements have been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods involved  and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments).  The Company is subject to the reporting requirements of the 1934 Act.

g. Absence of Certain Changes.  Since July 31, 2017, except as set forth in the SEC Documents, there has been no material adverse change and no material adverse development in the assets, liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act reporting status of the Company or any of its Subsidiaries.

h. Absence of Litigation.  Except as set forth in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material Adverse Effect.  The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

i. 

5

No Integrated Offering.  Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the 1933 Act of the issuance of the Securities to the Buyer.  The issuance of the Securities to the Buyer will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any shareholder approval provisions applicable to the Company or its securities.

j. No Brokers.  The Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated hereby. 

k. No Investment Company.  The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement will not be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment Company”).  The Company is not controlled by an Investment Company.

l. Breach of Representations and Warranties by the Company.  If the Company breaches any of the representations or warranties set forth in this Section 3, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of default under Section 3.4 of the Note.

4. COVENANTS.

a. Best Efforts.  The Company shall use its best efforts to satisfy timely each of the conditions described in Section 7 of this Agreement.  

b. Form D; Blue Sky Laws.  The Company agrees to timely make any filings required by federal and state laws as a result of the closing of the transactions contemplated by this Agreement.

 

c. Use of Proceeds.  The Company shall use the proceeds for general working capital purposes.

d. Expenses.  At the Closing, the Company’s obligation with respect to the transactions contemplated by this Agreement is to reimburse Buyer’ expenses shall be $3,000.00 for Buyer’s legal fees and due diligence fee. 

e. Corporate Existence.  So long as the Buyer beneficially owns any Note, the Company shall maintain its corporate existence and shall not sell all or substantially all of the Company’s assets, except with the prior written consent of the Buyer.

f. 

6

Breach of Covenants.  If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an event of default under Section 3.4 of the Note.

g. Failure to Comply with the 1934 Act.  So long as the Buyer beneficially owns the Note, the Company shall comply with the reporting requirements of the 1934 Act; and the Company shall continue to be subject to the reporting requirements of the 1934 Act.

h. Trading Activities.  Neither the Buyer nor its affiliates has an open short position in the common stock of the Company and the Buyer agrees that it shall not, and that it will cause its affiliates not to, engage in any short sales of or hedging transactions with respect to the common stock of the Company.

i. Right of First Refusal.  Unless it shall have first delivered to the Buyer, at least forty eight (48) hours prior to the closing of such Future Offering (as defined herein), written notice describing the proposed Future Offering (“ROFR Notice”), including the terms and conditions thereof, identity of the proposed purchaser and proposed definitive documentation to be entered into in connection therewith, and providing the Buyer an option during the forty eight (48) hour period following delivery of such notice to purchase the securities being offered in the Future Offering on the same terms as contemplated by such Future Offering (the limitations referred to in this sentence and the preceding sentence are collectively referred to as the “Right of First Refusal”), the Company will not conduct any equity (or debt with an equity component) financing in an amount less than $150,000 (“Future Offering(s)”) during the period beginning on the Closing Date and ending nine (9) months following the Closing Date.  In the event the terms and conditions of a proposed Future Offering are amended in any respect after delivery of the notice to the Buyer concerning the proposed Future Offering, the Company shall deliver a new notice to the Buyer describing the amended terms and conditions of the proposed Future Offering and the Buyer thereafter shall have an option during the forty eight (48) hour period following delivery of such new notice to purchase its pro rata share of the securities being offered on the same terms as contemplated by such proposed Future Offering, as amended.  Notwithstanding anything contained herein to the contrary, any subsequent offer by an investor, or an affiliate of such investor, identified on an ROFR Notice is subject to this Section 4(h) and the Right of First Refusal.

5. Transfer Agent Instructions.  The Company shall issue irrevocable instructions to its transfer agent to issue certificates, registered in the name of the Buyer or its nominee, for the Conversion Shares in such amounts as specified from time to time by the Buyer to the Company upon conversion of the Note in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”).  In the event that the Company proposes to replace its transfer agent, the Company shall provide, prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to this Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved Amount as such term is defined in the Note) signed by the successor transfer agent to Company and the Company. Prior to 

7

registration of the Conversion Shares under the 1933 Act or the date on which the Conversion Shares may be sold pursuant to an exemption from registration, all such certificates shall bear the restrictive legend specified in Section 2(e) of this Agreement.  The Company warrants that: (i) no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5, will be given by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company as and to the extent provided in this Agreement and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair, and/or hinder its transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate for Conversion Shares to be issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and this Agreement; and (iii) it will not fail to remove (or directs its transfer agent not to remove or impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions in respect thereof) on any certificate for any Conversion Shares issued to the Buyer upon conversion of or otherwise pursuant to the Note as and when required by the Note and/or this Agreement.  If the Buyer provides the Company and the Company’s transfer, at the cost of the Buyer, with an opinion of counsel in form, substance and scope customary for opinions in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the 1933 Act, the Company shall permit the transfer, and, in the case of the Conversion Shares, promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations as specified by the Buyer.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer, by vitiating the intent and purpose of the transactions contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Buyer shall be entitled, in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond or other security being required.

6. Conditions to the Company’s Obligation to Sell.  The obligation of the Company hereunder to issue and sell the Note to the Buyer at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions thereto, provided that these conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

a. The Buyer shall have executed this Agreement and delivered the same to the Company.

b. The Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

c. The representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at that time (except for representations and warranties that speak as of a specific date), and the Buyer shall have performed, satisfied and complied in all material respects with the covenants, agreements 

8

and conditions required by this Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date. 

d. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

7. Conditions to The Buyer’s Obligation to Purchase.  The obligation of the Buyer hereunder to purchase the Note at the Closing is subject to the satisfaction, at or before the Closing Date of each of the following conditions, provided that these conditions are for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion:

a. The Company shall have executed this Agreement and delivered the same to the Buyer.

b. The Company shall have delivered to the Buyer the duly executed Note (in such denominations as the Buyer shall request) in accordance with Section 1(b) above.

c. The Irrevocable Transfer Agent Instructions, in form and substance satisfactory to the Buyer, shall have been delivered to and acknowledged in writing by the Company’s Transfer Agent.

d. The representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of the Closing Date as though made at such time (except for representations and warranties that speak as of a specific date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date.  The Buyer shall have received a certificate or certificates, executed by the chief executive officer of the Company, dated as of the Closing Date, to the foregoing effect and as to such other matters as may be reasonably requested by the Buyer including, but not limited to certificates with respect to the Board of Directors’ resolutions relating to the transactions contemplated hereby.

e. No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

f. No event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but not limited to a change in the 1934 Act 

9

reporting status of the Company or the failure of the Company to be timely in its 1934 Act reporting obligations.

g. The Conversion Shares shall have been authorized for quotation on an exchange or electronic quotation system and trading in the Common Stock on such exchange or electronic quotation system shall not have been suspended by the SEC or an exchange or electronic quotation system.

8. Governing Law; Miscellaneous.

a. Governing Law.  This Agreement shall be governed by and construed in accordance with the laws of the State of Virginia without regard to principles of conflicts of laws.  Any action brought by either party against the other concerning the transactions contemplated by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the Eastern District of New York.  The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens.  The Company and Buyer waive trial by jury.  The prevailing party shall be entitled to recover from the other party its reasonable attorney's fees and costs.  In the event that any provision of this Agreement or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any such provision which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of any agreement.   Each party hereby irrevocably waives personal service of process and consents to process being served in any suit, action or proceeding in connection with this Agreement, the Note or any related document or agreement by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.  Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.

b. Counterparts.  This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.  

c. Headings.  The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this Agreement.

d. Severability.  In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed 

10

inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law.  Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision hereof.

e. Entire Agreement; Amendments.  This Agreement and the instruments referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters.  No provision of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest of the Buyer.

f. Notices.  All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party shall have specified most recently by written notice.  Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first occur.  The addresses for such communications shall be as set forth in the heading of this Agreement with a copy by fax only to (which copy shall not constitute notice) to Naidich Wurman LLP, 111 Great Neck Road, Suite 214, Great Neck, NY 11021, Attn: Allison Naidich, facsimile: 516-466-3555, e-mail: allison@nwlaw.com.  Each party shall provide notice to the other party of any change in address.

g. Successors and Assigns.  This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns.  Neither the Company nor the Buyer shall assign this Agreement or any rights or obligations hereunder without the prior written consent of the other.  Notwithstanding the foregoing, the Buyer may assign its rights hereunder to any person that purchases Securities in a private transaction from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

h. Survival.  The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer.  The Company agrees to indemnify and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result of or related to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

i. Further Assurances.  Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

j. No Strict Construction.  The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

k. Remedies.  The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the intent and purpose of the transaction contemplated hereby.  Accordingly, the Company acknowledges that the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Agreement, that the Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without the necessity of showing economic loss and without any bond or other security being required.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

Force Protection Video Equipment Corp.

By:________________________________

Paul Feldman

Chief Executive Officer and Chief Financial Officer 

POWER UP LENDING GROUP LTD.

By:

Name: Curt Kramer 

Title:   Chief Executive Officer

111 Great Neck Road, Suite 216

Great Neck, NY  11021

AGGREGATE SUBSCRIPTION AMOUNT:

Aggregate Principal Amount of Note:

$70,000.00

Aggregate Purchase Price:

$70,000.00

11EX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), is dated as of October 23, 2017, by and among ViewRay, Inc., a
Delaware corporation (the “Company”), and Strong Influence Limited, a British Virgin Islands corporation (the “Investor”) and Fosun International Limited, a company organized under the laws of Hong Kong (the
“Guarantor”). 
 RECITALS 

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the
Securities Act of 1933, as amended (the “Securities Act”), the Company desires to issue and sell to the Investor, and the Investor desires to purchase from the Company, securities of the Company as more fully described in this
Agreement; 
 WHEREAS, the Guarantor desires to guarantee the obligation of the Investor to pay the Purchase Price (as hereinafter defined)
upon the terms described herein; 
 WHEREAS, the Company has authorized, upon the terms and conditions stated in this Agreement, the sale
and issuance of 6,566,843 shares of the Company’s common stock, par value $0.01 per share (“Common Stock”); 

WHEREAS, at the Closing (as hereinafter defined), the Investor wishes to purchase, and the Company wishes to sell, upon the terms and
conditions stated in this Agreement, 6,566,843 shares of Common Stock (the “Shares”); 
 WHEREAS, contemporaneously with
the offering of the Shares, the Company is offering shares of Common Stock to certain other investors (the “Other Offering”); and 

WHEREAS, immediately after the Closing and the closing of the Other Offering, the Investor shall own 9.9% of the total outstanding shares of
Common Stock. 
 NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable
consideration the receipt and adequacy of which are hereby acknowledged, the Company, the Investor and the Guarantor agree as follows: 

ARTICLE 1 

DEFINITIONS 

1.1    Definitions.    In addition to the terms elsewhere in this Agreement, the following
terms have the meanings indicated: 

  
 -Securities Purchase
Agreement Page 1- 

 “Affiliate” means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 144 under the Securities Act. 

“Board” means the board of directors of the Company. 

“Business Day” means any day other than Saturday, Sunday or other day on which commercial banks in New York are authorized or
required by applicable law to remain closed. 
 “Change of Control Transaction” means (a) any transaction or series of
related transactions, whether or not the Company is a party thereto, in which, after giving effect to such transaction or transactions, Common Stock representing in excess of fifty percent (50%) of the voting power of the Company are owned directly,
or indirectly through one or more entities, by any “person” or “group” (as such terms are used in Section 13(d) of the Exchange Act) of Persons, (b) a sale, lease or other disposition of all or substantially all of the
assets of the Company and its Subsidiaries on a consolidated basis (including securities or interests of the Company’s directly or indirectly owned Subsidiaries) or (c) the exclusive licensing of substantially all of the Company’s
intellectual property. 
 “Common Stock” has the meaning ascribed to such term in the Recitals to this Agreement.

 “Commission” means the United States Securities and Exchange Commission. 

“Company Fundamental Representations” means the representations and warranties of the Company set forth in
Sections 4.1 (Organization and Qualification), 4.2 (Authorization; Enforcement), 4.5 (Valid Issuance) and 4.6 (Capitalization). 

“Effective Date” means the date and time as of which the S-3 Registration Statement
was declared effective by the Commission. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
rules and regulations of the Commission promulgated thereunder. 
 “Governmental Authority” means any transnational,
domestic or foreign federal, state or local governmental, regulatory or administrative authority, department, court, agency or official (including any court, tribunal or arbitral body) and any political subdivision thereof (including any authority
or political subdivision in the People’s Republic of China such as the National Development and Reform Commission, the Ministry of Commerce and the State Administration for Foreign Exchange and any of their respective local branches). 

“Investor Group” means the Investor and its affiliates and associates (as such terms are defined in Rule 12b-2 of the Exchange Act). 

  
 -Securities Purchase
Agreement Page 2- 

 “Lien” means, with respect to any asset, any pledge, lien, collateral
assignment, security interest, encumbrance, right of first refusal, mortgage, deed of trust, title retention, conditional sale or other security arrangement, or adverse claim of title. 

“Material Adverse Effect” means any of (a) a material adverse effect on the validity or enforceability of this Agreement,
(b) a material adverse effect on the condition (financial or otherwise), earnings, operations, assets, liabilities, business or properties of the Company and its Subsidiaries, taken as a whole, or (c) a material adverse effect on the
Company’s ability to perform its obligations under this Agreement or the Registration Rights Agreement. 
 “Person”
means any individual, corporation, limited liability company, partnership, joint venture, trust, incorporated or unincorporated association, joint stock company, unincorporated organization, a government or any department, subdivision or agency
thereof, or other entity of any kind. 
 “Subsidiary” means any direct or indirect subsidiary. 

“Transfer Agent” means American Stock Transfer & Trust Company, LLC or any successor transfer agent for the Company.

 ARTICLE 2 

PURCHASE AND SALE 

2.1    Purchase and Sale of the Shares.    Subject to the terms and conditions of this
Agreement, the Company shall issue and sell to the Investor, and the Investor shall purchase from the Company, 6,566,843 Shares for an aggregate purchase price of $39,072,715.85 (the “Purchase Price”). 

ARTICLE 3. 
 CLOSING
AND DELIVERY 
 3.1    Closing.    The closing (the “Closing”) of
the purchase and sale of the Shares shall take place on the date of this Agreement at the offices of Davis Polk & Wardwell LLP, 1600 El Camino Real, Menlo Park, California, (such date of the Closing, the “Closing
Date”). 
 3.2    Purchase of the Shares at the Closing.    At the Closing,
(a) the Investor shall deliver or cause to be delivered to the Company the aggregate Purchase Price in U.S. dollars in immediately available funds by wire transfer to the Company’s account, (b) the Company shall either
(i) deliver to the Investor evidence of a book entry position evidencing the Shares or (ii) issue one or more stock certificates registered in the name of the Investor, or in such nominee name(s) as designated by the Investor, representing
the number of Shares purchased by the Investor at the Closing against payment of the Purchase Price and (c) each of the Company and the Investor shall execute and deliver to each other a registration rights agreement (the “Registration
Rights Agreement”). 

  
 -Securities Purchase
Agreement Page 3- 

 ARTICLE 4 

REPRESENTATIONS, WARRANTIES OF THE COMPANY 

Except as otherwise described in the SEC Documents (as defined below) or in the Schedule of Exceptions delivered to the Investor concurrently
with this agreement (the “Schedule of Exceptions”), which disclosures qualify these representations and warranties in their entirety, the Company hereby represents and warrants to the Investor as follows: 

4.1    Organization and Qualification.    The Company and each of its material Subsidiaries
(i) has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Delaware, with full corporate power and authority to own or lease, as the case may be, and to operate its properties and
conduct its business as presently conducted, and (ii) is duly qualified to do business as a foreign corporation and is in good standing under the laws of each jurisdiction which requires such qualification, except in the case of
clause (ii) above, to the extent that the failure to be so qualified or be in good standing would not reasonably be expected to result in a Material Adverse Effect.

4.2    Authorization; Enforcement.    The execution, delivery and performance by the Company of
this Agreement and the Registration Rights Agreement (collectively, the “Transaction Documents”) and the consummation of the transactions contemplated hereby and thereby are within the corporate powers of the Company and have been duly
authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and delivered by the Company and constitutes a legal, valid and binding agreement of the Company, enforceable against it in accordance
with the terms hereof and thereof, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally. 

4.3    No Conflicts.    The execution, delivery and performance by the Company of the
Transaction Documents and the consummation of the transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of the Company’s certificate of incorporation or
by-laws; (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement to which the Company or any material Subsidiary is a party or by which any property or asset of the Company or any material Subsidiary is bound or
affected; or (iii) result in a violation of any applicable law, except, in the case of clause (ii) or (iii), to the extent that such conflict or violation has not had and would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect. 
 4.4    Governmental Authorization.    The execution,
delivery and performance by the Company of the Transaction Documents and the consummation of the transactions contemplated hereby and thereby require no approval or action by or filing with or notice to any Governmental Authority. 

  
 -Securities Purchase
Agreement Page 4- 

 4.5    Valid Issuance.    The Shares have been
duly authorized and, when issued and paid for in accordance with this Agreement, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens. 

4.6    Capitalization.

(a)    The authorized capital stock of the Company consists of 300,000,000 shares of Common Stock and 10,000,000 shares of
undesignated preferred stock, par value $0.01 per share (the “Preferred Stock”). As of the date hereof, there were no shares of Preferred Stock issued and outstanding and there were 59,071,653 shares of Common Stock issued and
outstanding, of which no shares are owned by the Company. There are no other shares of any other class or series of capital stock of the Company issued or outstanding. The Company has no capital stock reserved for issuance, except that there are
10,980,832 shares of Common Stock reserved for issuance pursuant to the Company’s 2008 Stock Option and Incentive Plan, 2015 Equity Incentive Plan (the “2015 Plan”) and 2015 Employee Stock Purchase Plan (the
“ESPP”) (as well as any automatic increases in the number of shares of the Company’s Common Stock reserved for future issuance under the 2015 Plan and ESPP) and outstanding warrants to purchase an aggregate of 3,428,248 shares
of Common Stock. There are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities having such rights) (“Voting Debt”) of the Company issued and outstanding. Except as stated
above, and except pursuant to the Other Offering, there are no existing options, warrants, calls, subscriptions or other rights, agreements, arrangements or commitments relating to the issued or unissued capital stock of the Company, obligating the
Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired any capital stock or Voting Debt of, or other equity interest in,
the Company or securities or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant, extend or enter into any such option, warrant, call, subscription or other right, agreement, arrangement
or commitment. The issuance of Shares pursuant to any provision of this Agreement will not give rise to any preemptive rights or rights of first refusal on behalf of any person or result in the triggering of any anti-dilution rights. 

(b)    Immediately following the Closing and the closing of the Other Offering, the Shares will represent 9.9% of the total
outstanding shares of Common Stock. 
 4.7    SEC Documents; Financial Statements.    The
Company has filed in a timely manner all documents that the Company was required to file with the Commission under Sections 13, 14(a) and 15(d) of the Exchange Act, since January 1, 2017. As of their respective filing dates (or, if amended
prior to the date of this Agreement, when amended), all documents filed by the Company with the Commission since January 1, 2017 (the “SEC Documents”) complied in all material respects with the requirements of the Exchange Act
and the rules and regulations of the Commission promulgated thereunder. None of the SEC Documents as of their respective dates contained any untrue statement of material fact or omitted to state a material fact

  
 -Securities Purchase
Agreement Page 5- 

 
required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they were made, not misleading. The financial statements of the Company
included in the SEC Documents (the “Financial Statements”) present fairly the financial condition, results of operations and cash flows of the Company as of the dates and for the periods indicated, comply as to form with the
applicable accounting requirements of the Act and have been prepared in conformity with generally accepted accounting principles applied on a consistent basis throughout the periods involved (except as otherwise noted therein). Deloitte &
Touche LLP, who have certified certain financial statements of the Company and delivered their report with respect to the audited consolidated financial statements and schedules included in the SEC Documents, are independent public accountants with
respect to the Company within the meaning of the Securities Act and the applicable published rules and regulations thereunder.

4.8    Registration Statement.    A registration statement on Form S-3 (No. 333-217416), including a form of prospectus (the “S-3 Registration Statement), relating to the Shares has been
filed with the Commission and has been declared effective. On the Effective Date of the S-3 Registration Statement, the Registration Statement conformed in all material respects to the requirements of the
Securities Act and the rules and regulations of the Commission (the “Rules and Regulations”) and did not include any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein not misleading. On the date of this Agreement, the S-3 Registration Statement and related prospectus each conform in all material respects to the requirements of the Securities Act and
the Rules and Regulations, and none of such documents includes any untrue statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading. 

4.9    Compliance.    Except as would not, individually or in the aggregate, result in a
Material Adverse Effect: (a) the Company is and has been in compliance with statutes, laws, ordinances, rules and regulations applicable to the Company for the ownership, testing, development, manufacture, packaging, processing, use, labeling,
storage, or disposal of any product manufactured by or on behalf of the Company or out-licensed by the Company (a “Company Product”), including without limitation, the Federal Food, Drug, and
Cosmetic Act, 21 U.S.C. § 301, et seq., the Public Health Service Act, 42 U.S.C. § 262, Health Insurance Portability and Accountability Act of 1996, as amended by Health Information Technology for Economic and Clinical
Health Act, or HIPPA, Export Administrations Act of 1979, Arms Export Contract Act, 35 U.S.C. Chapter 18, similar laws of other federal and state governmental entities and the regulations promulgated pursuant to such laws (collectively,
“Applicable Laws”); (b) the Company possesses all licenses, certificates, approvals, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws and/or for the ownership of its properties
or the conduct of its business as it relates to a Company Product and as described in the SEC Documents (collectively, “Authorizations”) and such Authorizations are valid and in full force and effect and the Company is not in
violation of any term of any such Authorizations; (c) the Company has not received any written notice of adverse finding, warning letter or other written correspondence or notice from the U.S. Food and Drug Administration (the “FDA”),
or any other federal and state governmental entity alleging or asserting noncompliance with any Applicable Laws or Authorizations relating to a Company Product; (d) the Company has not received written notice of any ongoing claim, action, suit,
proceeding, hearing, enforcement, 

  
 -Securities Purchase
Agreement Page 6- 

 
investigation, arbitration or other action from any governmental entity or third party alleging that any Company Product, operation or activity related to a Company Product is in violation of any
Applicable Laws or Authorizations or has any knowledge that any such governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding, nor, to the Company’s knowledge, has
there been any noncompliance with or violation of any Applicable Laws by the Company that would reasonably be expected to require the issuance of any such written notice or result in an investigation, corrective action, or enforcement action by the
FDA, or similar governmental entity with respect to a Company Product; (e) the Company has not received written notice that any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any
Authorizations or has any knowledge that any such governmental entity has threatened or is considering such action with respect to a Company Product; and (f) the Company has filed, obtained, maintained or submitted all reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete, correct and not misleading on the date filed (or were corrected or supplemented by a subsequent submission). 

4.10    Intellectual Property.    Except as would not, individually or in the aggregate, result
in a Material Adverse Effect: (a) the Company owns, possesses, licenses or has other rights to use, on reasonable terms, all of the Company’s patents, patent applications, trade and service marks, trade and service mark registrations,
trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual property (collectively, “Company Intellectual Property”) necessary for the conduct of
the Company’s business as now conducted or as proposed in the SEC Documents to be conducted, (b) to the knowledge of the Company, there are no rights of third parties to any Company Intellectual Property, other than as licensed by the
Company, and there is no infringement by third parties of any Company Intellectual Property (c) there is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s
rights in or to any Company Intellectual Property, challenging the validity or scope of any Company Intellectual Property or that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights
of others and (d) the Company is not aware of any facts required to be disclosed to the U.S. Patent and Trademark Office (“USPTO”) which have not been disclosed to the USPTO and which would preclude the grant of a patent in
connection with any patent application of the Company Intellectual Property or could form the basis of a finding of invalidity with respect to any issued patents of the Company Intellectual Property. 

4.11    Litigation.    No action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company or its property is pending or, to the best knowledge of the Company, threatened that will have a Material Adverse Effect, whether or not arising from transactions in the ordinary
course of business. 
 4.12    Taxes.    The Company has filed all tax returns that are
required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of business, except as
contemplated in the SEC Documents) and has paid all taxes required to be 

  
 -Securities Purchase
Agreement Page 7- 

 
paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is
currently being contested in good faith or as would not have a Material Adverse Effect, whether or not arising from transactions in the ordinary course of business, except as contemplated in the SEC Documents 

4.13    No Material Adverse Change.    Since June 30, 2017, there have not been any changes
in the authorized capital, assets, liabilities, financial condition, business, material contracts or operations of the Company from that reflected in the Financial Statements except changes in the ordinary course of business which have not been,
either individually or in the aggregate, materially adverse to the business, properties, financial condition or results of operations of the Company.

4.14    Voting Agreements.    Except for the stockholders’ agreement, dated as of
January 13, 2017, between and among the Company and the stockholders named therein, there are no shareholder agreements, voting agreements or other similar arrangements with respect to the voting of the Company’s capital stock (i) to
which the Company is a party or (ii) to the knowledge of the Company, between or among any of the Company’s stockholders. 

4.15    Price of Common Stock.    The Company has not taken, directly or indirectly, any action
designed to cause or result in, or that has constituted or that might reasonably be expected to constitute the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Shares. 

4.16    Brokers.    Neither the Company nor any of the officers, directors or employees of the
Company has employed any broker or finder or other Person in similar capacity in connection with the transaction contemplated by this Agreement. 

ARTICLE 5 

REPRESENTATIONS AND WARRANTIES OF THE INVESTOR AND THE GUARANTOR 

The Investor hereby represents and warrants to the Company as follows: 

5.1    Organization and Qualification.    The Guarantor and the Investor are each an entity duly
organized, validly existing and in good standing under the applicable laws of the jurisdiction of its incorporation or organization (as applicable). The Investor is an indirect wholly-owned Subsidiary of the Guarantor. The Guarantor is a company
organized under the laws of Hong Kong and listed on the Stock Exchange of Hong Kong Limited. 
 5.2    Authorization;
Enforcement.    The execution, delivery and performance by the Investor and the Guarantor of this Agreement and the consummation of the transactions contemplated hereby are within the corporate powers of the Investor and the
Guarantor and have been duly authorized by all necessary corporate action on the part of the Investor and the Guarantor. This Agreement has been duly executed and delivered by the Investor and the Guarantor and constitutes a legal, valid and binding
agreement of each of them, enforceable against each of them in accordance with the terms hereof and thereof, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally. 

  
 -Securities Purchase
Agreement Page 8- 

 5.4 Governmental Authorization. The execution, delivery and performance by the Investor
and the Guarantor of this Agreement and the consummation of the transactions contemplated hereby require no approval or action by or filing with or notice to any Governmental Authority. 

5.5 No Public Sale or Distribution. The Investor is acquiring the Shares not with a view towards, or for resale in connection with, the
public sale or distribution thereof, except pursuant to sales registered under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws, and the Investor does not have a
present arrangement to effect any distribution of the Shares to or through any Person. 
 5.6 Broker Fees. Neither the Investor nor
the Guarantor has employed any broker, investment banker, finder or other Person in a similar capacity in connection with this Agreement or the transactions contemplated hereby. 

5.7 Ownership of Company Securities. As of the date of this Agreement, the Investor (together with any member of the Investor Group)
beneficially owns 111,132 shares of Common Stock, and does not own any other equity or voting securities of the Company, or any options, warrants or other rights to acquire equity or voting securities of the Company or any other securities
convertible into equity securities of the Company. 
 5.8 Financing. At the Closing, the Investor will have sufficient cash of
immediately available U.S. Dollars to enable it to make payment of the Purchase Price. 
 5.9 Experience of the Investor and the
Guarantor. Each of the Investor and the Guarantor, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of
the prospective investment in the Shares, and has so evaluated the merits and risks of 

  
 -Securities Purchase
Agreement Page 9- 

 
such investment prior to entry into this Agreement. Each of the Investor and the Guarantor understands that it must bear the economic risk of this investment in the Shares, and is able to bear
such risk and is able to afford a complete loss of such investment. Each of the Investor and the Guarantor is, and will continue to be, solely responsible for making its own independent analysis of and investigations into the status,
creditworthiness, prospects, business, operations, assets and condition of the Company and its Subsidiaries and for making its own decision as to the purchase of, or the taking of any action in connection with, the Shares. 

5.10 Access to Information. Each of the Investor and the Guarantor acknowledges that it has had the opportunity to review this Agreement
and all publicly available records and filings by the Company, and has been afforded: (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and
conditions of the offering of the Shares and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects
sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed
investment decision with respect to the investment. Each of the Investor and the Guarantor also acknowledges that the Company would not enter into this transaction in the absence of the Investor’s representations and acknowledgments set forth
under Section 5.10 and this Section 5.11 and that these provisions, including such representations and acknowledgments, are a fundamental inducement to the Company, and that the Company would not enter into this transaction
but for this inducement. 
 ARTICLE 6 

OTHER AGREEMENTS OF THE PARTIES 

6.1 Lock-Up. The Investor hereby agrees not to sell, transfer or otherwise dispose of, directly
or indirectly, any Shares (including by entry into any swap or other arrangement that transfers to another Person any of the economic consequences of ownership of Shares) until 180 days after the Closing Date, except: (i) in connection with, or
after the closing of, a Change of Control Transaction; (ii) a transfer to an Affiliate of the Investor that is organized under the laws of any state in the United States of America, provided such Affiliate agrees in writing to be bound by the
terms of Sections 6.1 and 6.2 hereunder; (iii) a transfer to an Affiliate of the Investor that is not organized under the laws of any state in the United States of America, provided that the Company provides prior written
consent to such transfer (such consent not to be unreasonably withheld), and provided such Affiliate agrees in writing to be bound by the terms of Sections 6.1 and 6.2 hereunder; (iv) with prior Board approval; or
(v) upon a final non-appealable order issued by a Governmental Authority in the United States of America or the People’s Republic of China. 

6.2 Standstill. The Investor agrees that from the date hereof and until one year following the date hereof (the “Standstill
Period”), it will not, and will also ensure that no member of the Investor Group nor any Person acting on behalf of or in concert with the Investor nor any member of the Investor Group, will directly or indirectly, without the prior written

  
 -Securities Purchase
Agreement Page 10- 

 
consent of the Company: (i) acquire, agree to acquire, propose, seek or offer to acquire, or facilitate the acquisition or ownership of, any securities of the Company or any of its
Subsidiaries, or any warrant, option or other direct or indirect right to acquire any such securities that (taken together with all Shares and other voting securities held by the Investor Group) exceeds 19.9% of the then outstanding shares of Common
Stock; (ii) enter, agree to enter, propose, seek or offer to enter into or facilitate any merger, business combination, recapitalization, restructuring or other extraordinary transaction involving the Company or any of its Subsidiaries;
(iii) initiate, encourage, make, or in any way participate or engage in, any “solicitation” of “proxies” as such terms are used in the proxy rules of the Commission to vote, or seek to advise or influence any Person with
respect to the voting of, any voting securities of the Company; (iv) file with the Commission a proxy statement or any supplement thereof or any other soliciting material in respect of the Company or its stockholders that would be required to
be filed with the Commission pursuant to Rule 14a-12 or other provisions of the Exchange Act; (v) except as set forth in Sections 6.3 or 6.4, nominate or recommend for nomination a
Person for election at any stockholder meeting at which directors of the Company’s board of directors are to be elected; (vi) submit any stockholder proposal for consideration at, or bring any other business before, any Company stockholder
meeting; (vii) form, join or in any way participate in a “group” (within the meaning of Section 13(d)(3) of the Exchange Act) with respect to any voting securities of the Company; (ix) call, request the calling of, or
otherwise seek or assist in the calling of a special meeting of the stockholders of the Company; (x) otherwise act, alone or in concert with others, to seek to control or influence the management or the policies of the Company;
(xi) disclose any intention, plan or arrangement prohibited by, or inconsistent with, the foregoing; or (xii) advise, assist or encourage or enter into any discussions, negotiations, agreements or arrangements with any other Persons in
connection with the foregoing. 
 6.3 Observer Right. As long as the Investor and its Affiliates collectively beneficially own at
least 90% of the Shares purchased by them under this Agreement and do not have a representative on the Board, the Company shall invite one representative of the Investor (or an Affiliate of the Investor) (the “Observer”) to attend
all meetings of the Board in a nonvoting observer capacity and, concurrently with the delivery to the members of the Board, give to such Observer copies of all notices, minutes, consents, and other materials that it provides to its directors;
provided, however, that the Board shall have a right to approve the Observer (such approval not to be unreasonably withheld or delayed); provided, further, that the Observer executes and delivers to the Company a
customary confidentiality agreement prior to attending any Board meetings or receiving any such materials. If the Board does not approve of any Observer, then the Investor may select another individual for Board approval until an Observer is
approved. 
 6.4 Director Nomination Request Right. At any time following the Closing that the Investor and its Affiliates
collectively beneficially own at least 15% of the then outstanding shares of Common Stock, the Investor may, by written notice to the Company, request that one individual (the “Investor Nominee Director”) be appointed to the Board
as a director of the Company. Such request (a) may not be made more than once and (b) may not be made on or after the first date that the Investor and its Affiliates cease to collectively beneficially own at least 90% of the Shares
purchased by them under this Agreement. The Company shall use its reasonable best efforts to appoint the Investor Nominee Director to the Board within sixty (60) 

  
 -Securities Purchase
Agreement Page 11- 

 
days of the Company’s receipt of such request; provided, however, that the Investor Nominee Director executes and delivers to the Company a customary confidentiality agreement
prior to attending any Board meetings or receiving any related materials. In the event the Investor Nominee Director refuses or is unable to serve on the Board, the Investor shall be entitled to recommend any other individual to the Board as a
director, appointment of which individual shall be subject to approval by the Board (which such approval shall not be unreasonably withheld or delayed). If the Board does not approve of any Investor Nominee Director, then the Investor may select
another individual for Board approval until an Investor Nominee Director is approved. In furtherance of the foregoing, the Company shall include the name of the Investor Nominee Director (or any replacement nominee approved by the Board) in the
solicitation of proxies for election of directors for the next annual meeting of the Company, and shall not be required to include such individual’s name for any annual meeting thereafter. 

6.5 Publicity; Press Releases. No later than the Business Day immediately following the execution of this Agreement, the Company will
issue a press release disclosing the transactions contemplated by this Agreement. The Company and the Investor shall consult with each other in issuing any press releases with respect to the transactions contemplated hereby, and the Company and the
Investor shall not issue any such press release or otherwise make any such public statement or filing in connection with the transactions contemplated by this Agreement without the prior consent of the other party, which consent shall not be
unreasonably withheld, conditioned or delayed, except if such disclosure is required by applicable law (including the rules of any applicable stock exchange), in which case the disclosing party shall provide the other party with prior notice of such
public statement, filing or communication, and an opportunity to review such public statement, filing or communication. 
 6.6
Confidentiality After the Date Hereof. The Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, the Investor will maintain the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). 
 6.7 Securities Laws
Disclosure. The Company will timely and no later than four (4) Business Days from the date of this Agreement file a Current Report on Form 8-K with the Commission describing the terms of the
Transaction Documents (and including as exhibits to such Current Report on Form 8-K the agreements required to be filed in connection therewith). 

ARTICLE 7 

GUARANTEE. 
 7.1
Guarantee. The Guarantor hereby absolutely, unconditionally and irrevocably guarantees to the Company, as the primary obligor and not merely as surety, the due and timely observance, payment (to the extent applicable), performance and
discharge of the Investor’s obligations under this Agreement (the “Obligations”), including without limitation the payment of the Purchase Price at the Closing. If the Investor fails to perform any of the Obligations when due
pursuant to the terms of this Agreement, then the Guarantor’s liabilities to the Company hereunder in respect of such Obligations shall, at the Company’s option, become immediately 

  
 -Securities Purchase
Agreement Page 12- 

 
due and the Company may at any time and from time to time, at the Company’s option, take any and all actions available hereunder or under applicable law in respect of such Obligations,
including, if applicable, collecting the Purchase Price from the Guarantor. In furtherance of the foregoing, the Guarantor acknowledges that the Company may, in its sole discretion, bring and prosecute a separate action or actions against the
Guarantor in respect of the Obligations, regardless of whether any action is brought against the Investor. 
 ARTICLE 8 

INDEMNIFICATION 

8.1 Indemnification by the Company. From the Closing Date until the one year anniversary of the Closing Date (except indemnification
for inaccuracies in the Company Fundamental Representations, which shall not be subject to such time limit), the Company agrees to indemnify and hold harmless the Investor and each person, if any, who controls the Investor within the meaning of the
Securities Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities or expenses, joint or several, to which such Indemnified Party may become subject under the any federal or state statutory law or
regulation, or at common law (including in settlement of any litigation, if such settlement is effected with the prior written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof
as contemplated below) arise out of or are based in whole or in part on any inaccuracy in the representations and warranties of the Company contained in this Agreement or any failure of the Company to perform its obligations hereunder, and will
reimburse each Indemnified Party for legal and other expenses reasonably incurred as such expenses are reasonably incurred by such Indemnified Party in connection with investigating, defending, settling, compromising or paying such loss, claim,
damage, liability, expense or action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon (i) the failure of such
Indemnified Party to comply with the covenants and agreements contained in this Agreement, or (ii) the inaccuracy of any representations made by such Indemnified Party herein. 

ARTICLE 9 

MISCELLANEOUS 
 9.1
Fees and Expenses. Each party shall bear its own costs and expenses in connection with entry into this Agreement and the transactions contemplated hereby, including attorneys’ fees. The Company shall pay any transfer agent fees, stamp
taxes and other taxes and duties levied in connection with the sale and issuance of the Shares. 
 9.2 Waiver of Standstill. The
Company hereby waives the application of Section 9 of the Confidentiality and Standstill Agreement dated September 17, 2017 between the Company and Fosun Industrial Holdings Limited (the “CSA”) solely with respect to the
purchase by the Investor of the Shares pursuant to this Agreement. 
 9.3 Entire Agreement. This Agreement and the other documents
delivered in connection herewith, including the Registration Rights Agreement and the Schedule of 

  
 -Securities Purchase
Agreement Page 13- 

 
Exceptions, constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral
or written, with respect to such matters (except for any confidentiality obligations of the Investor or its Affiliates pursuant to the CSA). 

9.4 Notices. All notices, requests, consents and other communications hereunder shall be in writing, shall be sent or mailed by
first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so received in the case of mail or courier, and addressed as follows: 

Notices for the Company: 

2 Thermo Fisher Way 
 Oakwood
Village, Ohio 44146 
 Attention: Chris A. Raanes, CEO 

Facsimile: 800-417-3459 

Email: craanes@viewray.com 

and 
 815 E Middlefield Rd,

 Mountain View, CA 94043 

Attention: Chris A. Raanes, CEO 

Facsimile: 800-417-3459 

Email: craanes@viewray.com 

with a copy (which shall not constitute notice) to: 

Davis Polk & Wardwell LLP 

1600 El Camino Real, Menlo Park, CA 94025 

Attention: Alan Denenberg 

Facsimile: 650-752-2111 

Email: alan.denenberg@davispolk.com 

  
 -Securities Purchase
Agreement Page 14- 

 Notices for the Investor: 

2101 ICBC Tower 
 3 Garden Road

 Central, Hong Kong. 

Attention: Angel Sze, Company Secretary 

Facsimile: +852-2509-9028 

Email: angelsze@fosun.com 

Notices for the Guarantor: 

2101 ICBC Tower 
 3 Garden Road

 Central, Hong Kong. 

Attention: Angel Sze, Company Secretary 

Facsimile: +852-2509-9028 

Email: angelsze@fosun.com 

with a copy (which shall not constitute notice) to: 

DLA Piper LLP (US) 
 555 Mission
Street, Suite 2400 
 San Francisco, CA 94105 

Attention: Paul P Chen 

Facsimile: 415-659-7348 

Email: paul.chen@dlapiper.com 

Any party may give any notice, request, demand, claim or other communication hereunder using any other means (including personal delivery,
expedited courier, messenger service, telecopy, telex, ordinary mail or electronic mail), but no such notice, request, demand, claim or other communication shall be deemed to have been duly given unless and until it actually is received by the party
for whom it is intended. 
 9.5 Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written
instrument signed, in the case of an amendment, by each of the parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective. No waiver of any default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right
hereunder in any manner impair the exercise of any such right. 
 9.6 Construction. The headings herein are for convenience only, do
not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules
of strict construction will be applied against any party. 

  
 -Securities Purchase
Agreement Page 15- 

 
The parties acknowledge and agree that: (i) each party and its counsel have reviewed the terms and provisions of this Agreement and have contributed to its drafting; and (ii) the normal
rule of construction, to the effect that any ambiguities are resolved against the drafting party, shall not be employed in the interpretation of this Agreement. 

9.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor, and the Guarantor may not assign this Agreement or any rights or obligations hereunder without the
prior written consent of the Company. With the consent of the Company, which shall not be unreasonably withheld, the Investor may assign any or all of its rights under this Agreement to any Person to whom the Investor assigns or transfers any
Shares, provided, that the Investor may assign any or all rights under this Agreement to an Affiliate of the Investor without the consent of the Company, and provided, further: (i) such transferor agrees in writing with the
transferee or assignee to assign such rights, and a copy of such agreement is furnished to the Company after such assignment; (ii) the Company is furnished with written notice of the name and address of such transferee or assignee;
(iii) following such transfer or assignment, the further disposition of such securities by the transferee or assignee is restricted under the Securities Act and applicable state securities laws, unless such disposition was made pursuant to an
effective registration statement or an exemption under the Securities Act; (iv) such transferee agrees in writing to be bound, with respect to the transferred Shares, by the provisions of each of the Transaction Documents that apply to the
Investor; and (v) such transfer shall have been made in accordance with the applicable requirements of this Agreement and with all laws applicable thereto. 

9.8 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors and
permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person. 
 9.9 Governing Law;
Submission to Jurisdiction. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to any choice or conflict of law provision or rule (whether of the State of
Delaware or any other jurisdiction) that would cause the application of laws of any jurisdictions other than those of the State of Delaware. Each of the parties hereto irrevocably: (i) consents to the exclusive jurisdiction and venue of the
Delaware Court of Chancery and any state appellate court therefrom within the State of Delaware (or, if the Delaware Court of Chancery declines to accept jurisdiction over a particular matter, any state or federal court within the State of Delaware)
in connection with any matter based upon or arising out of the Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) or the matters contemplated by this
Agreement; (ii) agrees that process may be served upon them in any manner authorized by the laws of the State of Delaware for such persons; and (iii) waives and covenants not to assert or plead any objection it may now or hereafter have,
to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum, all to the fullest extent permitted by applicable
law. Any party may make service on another party by sending or delivering a copy of the process to the party to be served at the address and in the manner provided for the giving of notices in Section 9.3. Nothing in this
Section 9.8 however, shall affect the right of any party to serve legal process in any other manner permitted by law. 

  
 -Securities Purchase
Agreement Page 16- 

 9.10 WAIVER OF JURY TRIAL. EACH OF THE PARTIES IRREVOCABLY WAIVES ANY AND ALL RIGHTS TO
TRIAL BY JURY IN ANY ACTION OR PROCEEDING IN ANY JURISDICTION BETWEEN THE PARTIES ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

9.11 Survival. The representations and warranties contained herein shall survive the Closing. The agreements and covenants contained
herein shall survive the Closing in accordance with their respective terms. 
 9.12 Counterparts. This Agreement may be executed in
two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both
parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or email attachment, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such
signature is executed) with the same force and effect as if such facsimile or email-attached signature page were an original thereof. 
 9.13
Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect, the validity, illegality and enforceability of the remaining terms and provisions of this Agreement shall not in any way be
affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement. 

9.14 Replacement of Shares. If the Shares are certificated and any certificate or instrument evidencing any Shares is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably
satisfactory to the Company and the Company’s transfer agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that fact and an agreement to indemnify and hold harmless the
Company and the Company’s transfer agent for any losses in connection therewith or, if required by the transfer agent, a bond in such form and amount as is required by the transfer agent. The applicants for a new certificate or instrument under
such circumstances shall also pay any reasonable third-party costs associated with the issuance of such replacement Shares. If a replacement certificate or instrument evidencing any Shares is requested due to a mutilation thereof, the Company may
require delivery of such mutilated certificate or instrument as a condition precedent to any issuance of a replacement. 
 9.15 Remedies;
Specific Performance. The rights and remedies of the parties shall be cumulative (and not alternative). The parties agree that irreparable damage would occur if any 

  
 -Securities Purchase
Agreement Page 17- 

 
provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to an injunction or injunctions to prevent breaches of the Transaction
Documents or to enforce specifically the performance of the Transaction Documents, in addition to any other remedy to which they are entitled to at law or in equity, in each case without the requirement of posting any bond or other type of security.
Each of the parties agrees that it will not oppose the granting of an injunction, specific performance and other equitable relief on the basis that any other party has an adequate remedy at law or that any award of specific performance is not an
appropriate remedy for any reason at law or in equity. 
 [Signatures follow] 

  
 -Securities Purchase
Agreement Page 18- 

 IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly
executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Company:
	
	ViewRay, Inc.
		
	By:	 	/s/ Ajay Bansal
	Name: Ajay Bansal
	Title: Chief Financial Officer

  
 -Securities Purchase
Agreement Page 19- 

 
			
	Investor:
	
	Strong Influence Limited
		
	By:	 	/s/ Kevin Xie
	Name: Kevin Xie
	Title: Managing Director
	
	Guarantor:
	
	Fosun International Limited
		
	By:	 	/s/ Kevin Xie
	Name: Kevin Xie
	Title: Managing Director

  
 [Signature page to
Securities Purchase Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]